Serum Institute expected a decision on an Indian trial of Novavax's vaccine soon, Chief Executive Adar Poonawalla told news agency Reuters on Friday, hours after the US company reported the efficacy data.
"We have already applied to the drug controller's office for the bridging trial, a few days ago. So they should also give that approval soon now," Mr Poonawalla said.
Novavax's UK trial, which enrolled 15,000 people aged 18 to 84, is expected to be used to apply for use in Britain, the European Union, and other countries.
Serum Institute is already bulk producing a vaccine created by Oxford University and AstraZeneca, and Mr Poonawalla said earlier this month that his company would manufacture "upwards of 40-50 million doses per month" of the Novavax vaccine from around April.
Indian health officials say they generally ask for so-called bridging trials to figure out if a vaccine is safe and generates an immune response in its citizens whose genetic makeup can be different from people in western nations.
The efficacy of the Novavax vaccine was calculated at 95.6 per cent against the original coronavirus strain, and 85.6 per cent against the UK variant. But the level of protection was lower in a smaller, mid-stage trial conducted in South Africa.
Novavax said it began working on new shots against emerging strains in early January and expects to select ideal candidates in the coming days, then begin clinical testing in the second quarter of the year.
The Novavax vaccine was one of six candidates backed by a US government project formerly known as Operation Warp Speed, which has provided the company $1.75 billion. It's also being tested in a trial in the US and Mexico, which has recruited 16,000 of 30,000 participants.
Unlike the Pfizer, Moderna and AstraZeneca vaccines, which deliver the genetic instructions that make human cells create a key protein of the virus, the Novavax shot injects the proteins directly into the body to evoke an immune response.
Over 29 lakh healthcare and frontline workers so far since India began its COVID-19 vaccination drive two weeks ago using two locally-made shots - the AstraZeneca one from Serum Institute and another developed by Bharat Biotech and India's top clinical research body.
(With inputs from Reuters, AFP)
US Lawmakers Back Covid Chinese Lab Leak Theory After Two-Year Probe New XEC Covid Variant Spreads To 27 Countries, Here's What We Know So Far Study Shows How Long Covid Is Debilitating Children's Health Police Case Registered Against Rahul Gandhi For "Injuring" 2 BJP MPs Pakistan Tries To Arm-Twist China Over Gwadar Port. The Plan Backfires. "Human Error" Caused Chopper Crash That Killed CDS Bipin Rawat: Panel Report Indian Navy's New Missile Warship INS Tushil Sets Sail From Russia To India Remittances To India As Much As Pak, Bangladesh Budgets Combined: 5 Facts France Mass Rape: Who Received The Longest Prison Terms? Track Latest News Live on NDTV.com and get news updates from India and around the world.